期刊文献+

基于生物电子等排原理的核苷类HIV-1逆转录酶抑制剂研究进展

Review of the study of structure modification of HIV NRTIs on the principles of bioisosterism
下载PDF
导出
摘要 核苷类HIV逆转录酶抑制剂(NRTIs)作为逆转录酶的特异性抑制剂,是临床最早应用的一类抗HIV药物,至今仍发挥着重要的作用。NRTIs的应用有效地缓解症状,延长病程,对治疗AIDS有很好的效果。然而由于耐药毒株及毒副作用的出现,NRTIs的疗效受到很大限制,因此研发高效、低毒、耐突变的新型NRTIs仍然是目前的热点之一。通过生物电子等排原理对核苷类药物进行广泛的结构修饰是获得高效、低毒、具有较高生物利用度的新型药物的有效途径。本文综述了该领域的研究进展。 HIV nucleoside reverse transcriptase inhibitors (NRTIs),as a kind of specific reverse transcriptase inhibitors and the earliest clinical applications of anti-HIV drugs, are still playing an important role. In the treatment of AIDS, NRTIs can effectively alleviate the symptoms and extend the duration. However, because of the drug-resistant strains and the toxico- logical side-effects,the efficacy of NRTIs has been greatly restricted. So R & D,a new type of NRTIs which has high efficiency, low toxicity and resistance mutations,is still one of the most widely applied in the present time. By the principles of the bioisos- terism,the comprehensive structure modification of nucleoside drugs is an efficient way to develop a new drug with low toxin, high bioavailability and powerful effect. This paper is an attempted review of the study and research in this field.
出处 《齐鲁药事》 2009年第3期170-173,共4页 qilu pharmaceutical affairs
关键词 Ⅰ型HIV病毒 逆转录酶抑制剂 生物电子等排原理 HIV- 1 NRTIs bioisosterism
  • 相关文献

参考文献22

  • 1Telesnitsky A,Goff SP. Reverse transcription and the generation of viral DNA. In.. Coffin JM, Hughes SH, Varmus HE, Retroviruses. NY : Cold Spring Harbor Laboratory Press, 1997 : 121-160.
  • 2Huang H, Choora R, Verdine GL, et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science, 1998,282 (5394) : 1669-1675.
  • 3Nikolenko GN,Frankenberry KA,Palmer S, et al. RNase H domains obtained from treatment-experienced patients increase resistance to AZT. Antiviral Therapy, 2005,10 : S89.
  • 4Sarafianos SG,Das K, Hughes SH. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transeriptases. Curr Opin Struet Biol, 2004,14 (6) : 716-730.
  • 5Janice DP,William GS,Steven W,et al. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant retranscriptases resistant to other nonnueleoside inhibitors. PNAS,2004,101(29) :10548-10553.
  • 6Gupta SP. Advances in QSAR studies of HIV- 1 reverse transcriptase inhibitors. Prog Dr Res, 2002,58 : 223.
  • 7Ding J, Das K, Hsiou Y, et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with double-stranded DNA and an antibody Fab fragment at 2.8a resolution. J Mol Biol,1998,284:1095-1111.
  • 8Kouni M H. Trends in the design of nueleoside analogues as anti- HIV drugs. Curr Pharm Des,2002,8(8) :581.
  • 9De Clercq E. Antiviral drug discovery and development: Where chemistry meets with biomedicine. Antiviral Research, 2005,67 (2):56-75.
  • 10Menendez Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci,2002,23 (8) :381-388.

二级参考文献69

  • 1Levene P A, Jacobs W A. Chem. Bet., 1909, 42:2474-2478.
  • 2De Clerq E. Adv. Drug Res., 1988, 17:1.
  • 3Chu C K, Baker D C. Nucleosides and Nucleotides as Antitumor Agents and Antiviral Agens. New York: Flemun Press, 1993.
  • 4De Clerq E. J. Med. Chem., 1995, 38:2491-2517.
  • 5Gumina G, Clmng Y, Song G Y, Chu C K. Cunnent Topics in Medicinal Chemistry, 2002, 2:1065-1066.
  • 6Lin T S, Luo M Z, Liu M C. Tetrahedron Lett., 1994, 35:3477.
  • 7Chu C K, Ahn S K, Kim H O, et al. Tetrahedron Lett., 1991,32:3791.
  • 8Kim H O, Schinazi R F,Shanmuganathan K, et al. J. Med.Chem., 1993, 36:519.
  • 9Bolon P, Wang P, Chu C K, et al. Bioorg. Med. Chem. Lett.,1996, 6:1657.
  • 10Chang C N, Dongs L, Zhou J H, et al. J. Biol. Chem., 1992,267 : 13938- 13942.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部